At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- ADX-038 Dose Level 2 (drug), ADX-038 Dose Level 1 (drug)
- How long the study runs
- Study runs about 46 months (dates as stated)
- About the drug or intervention
- ADX-038 Dose Level 2 — drug: siRNA duplex oligonucleotide · ADX-038 Dose Level 1 — drug: siRNA duplex oligonucleotide
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 45
- Started
- 2025-08-28
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for igan
- • Phase2 - 45 participants
- • This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with igan
Where?
- • Leicester - ADARx Clinical Site
- • Newcastle upon Tyne - ADARx Clinical Site
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
IgANC3GComplement-mediated Kidney DiseaseIgA Nephropathy (IgAN)IC-MPGN
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Biomarkers mentioned
eGFR
Treatment history
Treatments you must have had:
- ✓ vaccinations
What the study is looking for
- ✓Mean eGFR greater than or equal to 30 mL/min/1.73m2
- ✓Clinical evidence of active kidney disease
- ✓Treated with supportive care including an ACE inhibitor or ARB if applicable
- ✓Willing to receive required vaccinations
- ✓Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
Who cannot take part
- ✗Hereditary or acquired complement deficiency
- ✗Kidney transplant or kidney replacement therapy
- ✗History of solid organ transplant
- ✗Other kidney disease
- ✗History of recurrent invasive infections
See the full criteria
Inclusion Criteria:
* Mean eGFR greater than or equal to 30 mL/min/1.73m2
* Clinical evidence of active kidney disease
* Treated with supportive care including an ACE inhibitor or ARB if applicable
* Willing to receive required vaccinations
* Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
Exclusion Criteria:
* Hereditary or acquired complement deficiency
* Kidney transplant or renal replacement therapy
* History of solid organ transplant
* Other kidney disease
* History of recurrent invasive infections
* Received complement inhibitor treatments
* Active systemic viral, bacterial, or fungal infection
* Abnormal liver function
Where Is This Study? (2 UK sites)
ADARx Clinical Site
Leicester LE5 4PW, United Kingdom
ADARx Clinical Site
Newcastle upon Tyne UK, NE7 7DN, United Kingdom
How to Get in Touch
Tracy Nguyen
Sponsor contactCONTACT
877-232-7974 info@adarx.com
Data sourced from ClinicalTrials.gov · Last verified: 2026-09